Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment and diagnosis of cancer in the United States and internationally. The company’s lead immunotherapy candidate, bavituximab, which is in Phase III development stage for the treatment of previously-treated non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. It is also involved in the development of molecular imaging agent, 124I-PGN650, which is in exploratory clinical trial for the imaging of various solid tumor types. The company provides current good manufacturing practice services from cell line development to commercial biomanufacturing for its third-party customers. It has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA.; and collaboration agreement with AstraZeneca PLC for immuno-oncology combination clinical trial, as well as with the National Comprehensive Cancer Network. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.